FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214606790> ?p ?o ?g. }

• W3214606790 endingPage "2661" @default.
• W3214606790 startingPage "2661" @default.
• W3214606790 abstract "Abstract INTRODUCTION: Although the treatment of patients with multiple myeloma (MM) has dramatically improved, those with high-risk characteristics, including the deletion or mutation of the master tumor suppressor gene TP53 on chromosome 17, experience limited survival. OM301 is a synthetic polypeptide containing the p53TA (transactivation) domain, which prevents p53 degradation through inhibition of MDM2. Here, we demonstrate that OM301 has strong anti-MM activity in vitro and in vivo. RESULTS: We first assessed the cytotoxic effects of OM301 in MM cell lines with varying TP53 status (TP53 wild type: MM.1S, H929; TP53 mutated/null: L363, RPMI-8226, U266, JJN3, KMS11) and found that OM301 exerts significant cytotoxic effects at a concentration of ~5 µM in all cell lines we tested, while it was minimally toxic to human peripheral blood mononuclear cells. Next, using immunocompromised NSG mice models injected with MM.1S, we determined the in vivo efficacy of OM301 in three different studies. Many potent anticancer agents, particularly of peptide origin, show prominent anti-tumor effects but fail to sustain similar effects when given intraperitoneally because of poor absorption, distribution, metabolism and excretion properties. OM301 at an intraperitoneal dose of 20 mg/kg/body weight twice a day induced significant reduction in tumor size with respect to vehicle control, suggesting the stability of OM301 without any loss of its activity (n=7, p&lt;0.0001). Accordingly, we investigated its effect in a disseminated NSG/MM.1S model and found that it significantly increased survival (p&lt;0.0001) (see Figure). Because OM301 was designed to simulate the p53 interaction domain with MDM2, we first determined its effect on p53-MDM2 crosstalk using a p53-MDM2 co-Immunoprecipitation (co-IP) assay and compared it with effects from Nutlin-3a, a known inhibitor of p53-MDM2. The co-IP data showed that, unlike Nutlin-3a, OM301 does not inhibit the p53-MDM2 interaction. Thus, to confirm our findings, we first overexpressed MDM2 in HeLa cells, and, using MDM2-IP and p53-MDM2 co-IP, found similar observations. Additionally, OM301 also failed to induce endogenous upregulation of genes activated by p53, such as MDM2 and p21, as opposed to results from Nutlin-3a. RNA sequencing data also showed a distinctive OM301signature, as compared to Nutlin-3a in MM cells. While treatment of Nutlin-3a induced expression of p53-activated canonical genes, OM301-treated cells showed alterations in genes involved in inflammatory responses, c-Myc regulated genes, fatty acid metabolism, glucose metabolism, and oxidative phosphorylation, among others. Next, to dissect its underlying mechanism, we dual-tagged OM301 with fluorophores at the 3' and 5' ends to study its localization and its stability in MM cells. Indeed, OM301 was found to be stable and mainly localized in the cytosol. We then modified OM301 by biotinylation of its penetratin end and first verified its cytotoxic effect in different MM cell lines, which was similar to that of native OM301. The biotinylated OM301 was then immunoprecipitated using streptavidin beads. The streptavidin pull-down and subsequent proteomic analysis confirmed that OM301 does not interact with MDM2 but interacts with c-Myc and with proteins localized in mitochondria, including Bcl-2 and Bcl-2 family members such as Bclaf1, Bcl2L13, and Bcl2L1. Pull-down experiments and immunoblot analysis validated Bcl-2/OM301 interactions. To further evaluate the relative binding potentials of OM301, we performed molecular docking studies using the HPEPDOCK server (Yan et al., Nat Protoc. 2020;15:1829). Post-docking, the calculated docking scores for OM301 was -281, suggesting that OM301directly interacts with Bcl-2. Thus, we evaluated the effects of OM301 on mitochondrial function and physiology. Treatment with OM301 decreased mitochondrial membrane potential in different MM cell lines. OM301 also increased mitochondrial superoxide production and induced mitophagy and mitochondrial fission as seen by electron microscopy. CONCLUSION: Here, we report for the first time that OM301, although designed for p53-selective cells, may instead interact with Bcl-2, which in turn induces mitochondrial dysfunction, leading to cell death irrespective of their TP53 status. Our data suggest that OM301 may be a novel and effective therapeutic option for MM. Figure 1 Figure 1. Disclosures Krishnan: REGENERON: Consultancy; MAGENTA: Consultancy; BMS: Consultancy, Current equity holder in publicly-traded company, Speakers Bureau; JANSSEN: Consultancy, Research Funding; City of Hope Cancer Center: Current Employment; SANOFI: Consultancy; GSK: Consultancy; Amgen: Speakers Bureau. Marcucci: Novartis: Other: Speaker and advisory scientific board meetings; Agios: Other: Speaker and advisory scientific board meetings; Abbvie: Other: Speaker and advisory scientific board meetings." @default.
• W3214606790 created "2021-11-22" @default.
• W3214606790 creator A5013186731 @default.
• W3214606790 creator A5017148236 @default.
• W3214606790 creator A5022049231 @default.
• W3214606790 creator A5024513713 @default.
• W3214606790 creator A5034550055 @default.
• W3214606790 creator A5035985145 @default.
• W3214606790 creator A5039118991 @default.
• W3214606790 creator A5040853374 @default.
• W3214606790 creator A5048042606 @default.
• W3214606790 creator A5070878141 @default.
• W3214606790 date "2021-11-05" @default.
• W3214606790 modified "2023-09-30" @default.
• W3214606790 title "OM301, a Synthetic Polypeptide Containing the p53TA (Transactivation) Domain, Impairs Mitochondrial Activity and Survival of Myeloma Cells" @default.
• W3214606790 doi "https://doi.org/10.1182/blood-2021-151506" @default.
• W3214606790 hasPublicationYear "2021" @default.
• W3214606790 type Work @default.
• W3214606790 sameAs 3214606790 @default.
• W3214606790 citedByCount "0" @default.
• W3214606790 crossrefType "journal-article" @default.
• W3214606790 hasAuthorship W3214606790A5013186731 @default.
• W3214606790 hasAuthorship W3214606790A5017148236 @default.
• W3214606790 hasAuthorship W3214606790A5022049231 @default.
• W3214606790 hasAuthorship W3214606790A5024513713 @default.
• W3214606790 hasAuthorship W3214606790A5034550055 @default.
• W3214606790 hasAuthorship W3214606790A5035985145 @default.
• W3214606790 hasAuthorship W3214606790A5039118991 @default.
• W3214606790 hasAuthorship W3214606790A5040853374 @default.
• W3214606790 hasAuthorship W3214606790A5048042606 @default.
• W3214606790 hasAuthorship W3214606790A5070878141 @default.
• W3214606790 hasBestOaLocation W32146067901 @default.
• W3214606790 hasConcept C104317684 @default.
• W3214606790 hasConcept C1292079 @default.
• W3214606790 hasConcept C137061746 @default.
• W3214606790 hasConcept C150194340 @default.
• W3214606790 hasConcept C153911025 @default.
• W3214606790 hasConcept C154317977 @default.
• W3214606790 hasConcept C185592680 @default.
• W3214606790 hasConcept C190283241 @default.
• W3214606790 hasConcept C202751555 @default.
• W3214606790 hasConcept C203014093 @default.
• W3214606790 hasConcept C207001950 @default.
• W3214606790 hasConcept C502942594 @default.
• W3214606790 hasConcept C54355233 @default.
• W3214606790 hasConcept C55493867 @default.
• W3214606790 hasConcept C81885089 @default.
• W3214606790 hasConcept C86803240 @default.
• W3214606790 hasConceptScore W3214606790C104317684 @default.
• W3214606790 hasConceptScore W3214606790C1292079 @default.
• W3214606790 hasConceptScore W3214606790C137061746 @default.
• W3214606790 hasConceptScore W3214606790C150194340 @default.
• W3214606790 hasConceptScore W3214606790C153911025 @default.
• W3214606790 hasConceptScore W3214606790C154317977 @default.
• W3214606790 hasConceptScore W3214606790C185592680 @default.
• W3214606790 hasConceptScore W3214606790C190283241 @default.
• W3214606790 hasConceptScore W3214606790C202751555 @default.
• W3214606790 hasConceptScore W3214606790C203014093 @default.
• W3214606790 hasConceptScore W3214606790C207001950 @default.
• W3214606790 hasConceptScore W3214606790C502942594 @default.
• W3214606790 hasConceptScore W3214606790C54355233 @default.
• W3214606790 hasConceptScore W3214606790C55493867 @default.
• W3214606790 hasConceptScore W3214606790C81885089 @default.
• W3214606790 hasConceptScore W3214606790C86803240 @default.
• W3214606790 hasIssue "Supplement 1" @default.
• W3214606790 hasLocation W32146067901 @default.
• W3214606790 hasOpenAccess W3214606790 @default.
• W3214606790 hasPrimaryLocation W32146067901 @default.
• W3214606790 hasRelatedWork W1528770089 @default.
• W3214606790 hasRelatedWork W2011179920 @default.
• W3214606790 hasRelatedWork W2050306700 @default.
• W3214606790 hasRelatedWork W2080089609 @default.
• W3214606790 hasRelatedWork W2291104341 @default.
• W3214606790 hasRelatedWork W2382426014 @default.
• W3214606790 hasRelatedWork W2385215236 @default.
• W3214606790 hasRelatedWork W2419403076 @default.
• W3214606790 hasRelatedWork W2595339019 @default.
• W3214606790 hasRelatedWork W4313310672 @default.
• W3214606790 hasVolume "138" @default.
• W3214606790 isParatext "false" @default.
• W3214606790 isRetracted "false" @default.
• W3214606790 magId "3214606790" @default.
• W3214606790 workType "article" @default.